I’m excited for CYDY to finally get the mTNBC trial going. Preclinical results are very good and if leronlimab can perform like miranovic but with basically zero side effects, CYDY, investors and patients with cancer will benefit greatly. Although I don’t think NP will won his bet because of the delay, I think cancer is what will get CYDY above $2, uplisted, and eventually many, many multiples of the current PPS.

With RPs departure, which was at least partly related to the mTNBC delay, hopefully the trial will fill up at a decent phase. I’m hopeful that CYDY will give us a tentative timeline on prelim results.